Sen-Jam Pharmaceutical, an innovative life sciences company, announced on Friday that it has started enrolling patients into its phase two Clinical Trial for a potential oral COVID therapeutic in Nepal.
The company has also collaborated with KVK Tech that will offer access to Formulation and Chemistry, Manufacturing & Controls (CMC) for its COVID-19 therapeutic.
SJP-002C, Sen-Jam Pharmaceutical's investigational therapeutic for the treatment of COVID-19, is now enrolling patients for the clinical trial under a co-development agreement with Duke-NUS and Duke University School of Medicine.
Dr Alexander T Limkakeng Jr, MD, MHSc, FACEP, Professor, vice chief of Research and director, Acute Care Research at Duke Emergency Medicine, said, 'The study design has several unique features, including using a combination therapy that is widely available as an approved drug in countries around the world; has a known safety profile and well-understood mechanism of action of its individual components; has been studied in other viral illnesses; and could have complementary effects, with one agent potentially reducing the known side effects of the other.'
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial